Jefferies Financial Group reaffirmed a 'buy' rating and issued a $45.00 target price for NewAmsterdam Pharma, Inc.
1 report, 1 independent
Updated Sep 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jefferies Financial Group reaffirmed a 'buy' rating and issued a $45.00 target price for NewAmsterdam Pharma, Inc.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Jefferies Financial Group
American financial services company
-
Royal Bank of Canada
financial institution in Canada
Related events
- MarketBeat reports consensus ratings from sixteen brokerages, including RBC's 'outperform' rating and Scotiabank's target price cut for Lightspeed.
- Price targets for UDR were adjusted by Cantor Fitzgerald, Scotiabank, and Royal Bank of Canada on May 26, 2026.
- Multiple financial firms, including Keefe, Bruyette & Woods, Jefferies, and TD Cowen, adjusted price targets and ratings on September 24, 2026.
- Analyst firms RBC and Morgan Stanley set price targets for OTIS, with MarketBeat aggregating the ratings.
- Royal Bank of Canada and Morgan Stanley lowered price targets for Amentum stock in August 2026.